Form 4: agilon health Director Awarded 2,133 RSUs

Director Sharad Mansukani received a grant of 2,133 restricted stock units as part of his compensation, following a significant reverse stock split earlier this year.

Summary

• Sharad Mansukani, a director at agilon health, inc., was granted 2,133 restricted stock units (RSUs) on June 2, 2026.
• The RSUs are scheduled to vest in full on June 2, 2027, provided the director continues his service with the company.
• Following this acquisition, Mansukani's total beneficial ownership is 56,242 shares of common stock.
• The reported share amounts reflect a 1-for-25 reverse stock split that was executed on March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event; while insider ownership is positive, the context of a heavy reverse split earlier in the year suggests historical performance challenges.

Positives

• Director compensation is aligned with shareholder interests through equity-based grants.
• The director maintains a substantial ownership stake of 56,242 shares, indicating long-term commitment.

Negatives

• The issuance of new RSUs results in minor dilution for existing shareholders.
• The mention of a 1-for-25 reverse stock split typically suggests the company faced significant share price pressure or listing compliance issues in the recent past.

Risks

• Vesting is contingent on continued service, which could be impacted by board turnover.
• The value of the equity grant is subject to market volatility and the company's ability to improve its share price post-reverse split.

Future Outlook

The director is expected to remain on the board through at least June 2027 to realize the full value of the equity grant.

Management Comments

• Restricted stock units vest in full on June 2, 2027, subject to continued service as a director.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard industry practice to ensure board members are incentivized to drive long-term shareholder value, particularly in the evolving value-based healthcare sector.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with peers such as Oak Street Health and Privia Health.
• A 1-for-25 reverse split is significantly more aggressive than the typical 1-for-5 or 1-for-10 splits often seen in the mid-cap healthcare space.

Corporate Governance

Related Party Transactions

• The grant of RSUs to a director constitutes a related party transaction in the form of executive/director compensation.

Stakeholder Impact

• Shareholders experience minor dilution from the potential issuance of 2,133 new shares.
• The director is incentivized to remain with the company for the next 12 months.

Next Steps

• Vesting of the 2,133 RSUs on June 2, 2027.

Key Dates

Recommendation

This filing represents a routine compensation event. While insider equity grants are generally positive, the recent 1-for-25 reverse split indicates the company may still be in a recovery phase, making a 'hold' rating appropriate until further financial performance is demonstrated.

Keywords

agilon health, AGL, Insider Trading, Form 4, Restricted Stock Units, Director Compensation, Reverse Stock Split, Healthcare Services